Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020822 · ClinicalTrials.gov registry record · NA
Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT04020822: Completed NA study, sponsored by Medtronic MiniMed.
NCT04020822 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04020822, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.
Interventions
- DEVICE Guardian Sensor (3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2019-08-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04020822
The ClinicalTrials.gov registry entry for NCT04020822 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic MiniMed, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guardian Sensor (3) is the first listed.
NCT04020822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04020822 about?
NCT04020822 is a clinical study titled "Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices". The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.
What is the current status of trial NCT04020822?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2019-07-29. Estimated completion is 2019-08-27.
What interventions are being tested in trial NCT04020822?
The interventions under investigation include: Guardian Sensor (3) (DEVICE).
Who is sponsoring clinical trial NCT04020822?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.